201 related articles for article (PubMed ID: 15385083)
1. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.
Kirsch GE; Trepakova ES; Brimecombe JC; Sidach SS; Erickson HD; Kochan MC; Shyjka LM; Lacerda AE; Brown AM
J Pharmacol Toxicol Methods; 2004; 50(2):93-101. PubMed ID: 15385083
[TBL] [Abstract][Full Text] [Related]
2. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature.
Yao JA; Du X; Lu D; Baker RL; Daharsh E; Atterson P
J Pharmacol Toxicol Methods; 2005; 52(1):146-53. PubMed ID: 15936218
[TBL] [Abstract][Full Text] [Related]
3. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
4. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
5. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
6. The action of a novel fluoroquinolone antibiotic agent antofloxacin hydrochloride on human-ether-à-go-go-related gene potassium channel.
Guo J; Han SN; Liu JX; Zhang XM; Hu ZS; Shi J; Zhang LR; Zhao ZZ; Zhang Z
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):643-9. PubMed ID: 20662825
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
Teschemacher AG; Seward EP; Hancox JC; Witchel HJ
Br J Pharmacol; 1999 Sep; 128(2):479-85. PubMed ID: 10510461
[TBL] [Abstract][Full Text] [Related]
8. hERG potency estimates based upon dose solution analysis: What have we learned?
Qu Y; Schnier P; Zanon R; Vargas HM
J Pharmacol Toxicol Methods; 2011; 64(3):251-7. PubMed ID: 21888984
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.
Paul AA; Witchel HJ; Hancox JC
Br J Pharmacol; 2002 Jul; 136(5):717-29. PubMed ID: 12086981
[TBL] [Abstract][Full Text] [Related]
10. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.
Katchman AN; McGroary KA; Kilborn MJ; Kornick CA; Manfredi PL; Woosley RL; Ebert SN
J Pharmacol Exp Ther; 2002 Nov; 303(2):688-94. PubMed ID: 12388652
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
Sorota S; Zhang XS; Margulis M; Tucker K; Priestley T
Assay Drug Dev Technol; 2005 Feb; 3(1):47-57. PubMed ID: 15798395
[TBL] [Abstract][Full Text] [Related]
12. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656.
Siebrands CC; Schmitt N; Friederich P
Anesthesiology; 2005 Jul; 103(1):102-12. PubMed ID: 15983462
[TBL] [Abstract][Full Text] [Related]
13. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
[TBL] [Abstract][Full Text] [Related]
14. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
16. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
17. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
18. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
20. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
